BV Khan, S Sola, WB Lauten, R Natarajan, … - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—After 4 weeks of therapy, serum 8-isoprostane was reduced by 12% in
the quinapril group when compared with placebo (quinapril, 46.7 ± 1.0; placebo,
52.7 ± 0.9 pg/ml; P = 0.001). Erythrocyte superoxide dismutase activity ... Cited by 28 - Related articles - BL Direct - All 5 versions
S Nagamia, A Pandian, F Cheema, R … - Prev Cardiol, 2007 - interscience.wiley.com Forty-four patients with the metabolic syndrome were placed on a reduced-calorie
and reduced-fat regimen to lose weight throughout a 56-week period. The patients
were treated in a crossover fashion with placebo and the ... Cited by 4 - Related articles - All 2 versions
A Lazaro, J Gallego-Delgado, P Justo, V … - Antioxidants & Redox Signaling, 2005 - liebertonline.com A RTERIAL HYPERTENSION is a leading cause of end-stage renal disease and
contributes to the progression of other forms of chronic renal disease (22, 29).
Hypertensive nephrosclerosis is characterized by glomerular and arterioar- ... Cited by 13 - Related articles - BL Direct - All 3 versions
J Krützfeldt, W Raasch, HH Klein - Naunyn-Schmiedeberg's Archives of Pharmacology, 2000 - Springer Abstract To investigate mechanisms by which angio- tensin converting enzyme
(ACE)-inhibition increases in- sulin sensitivity, spontaneously hypertensive
(SH) rats were treated with or without ramipril (1 mg/kg per day) for 12 ... Cited by 15 - Related articles - BL Direct - All 2 versions
- ►ahajournals.org S Sola, MQS Mir, FA Cheema, N Khan- … - Circulation, 2005 - Am Heart Assoc Methods and Results— We randomized 58 subjects with the metabolic syndrome in
a double-blinded manner to irbesartan 150 mg/d (n=14), lipoic acid 300 mg/d
(n=15), both irbesartan and lipoic acid (n=15), or matching placebo (n=14) ... Cited by 109 - Related articles - All 12 versions
[CITATION] Влияние эналаприла на суточный профиль артериального давления и клинико- …
G Mancia, M Weber - Journal of hypertension. Supplement: official journal of …, 2003 - ncbi.nlm.nih.gov 1: J Hypertens Suppl. 2003 Jul;21(6):S1-2. A new dawn in cardiovascular protection:
blood pressure lowering through AT1 blockade. Introduction. ... Cited by 2 - Related articles - All 2 versions
